The Department of Health and Human Services (HHS) Aug. 19 announced a policy aimed at restricting the FDA’s regulation of laboratory-developed tests (LDTs) — in vitro diagnostic (IVD) tests that are designed, manufactured and used within a single laboratory. Under the policy, the FDA cannot require premarket review of LDTs “absent notice-and-comment rulemaking, as opposed to ... Read More